Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Bardoxolone Methyl in Autosomal Dominant Polycystic Kidney Disease
jRCT2080225066Phase 3Completed
- Sponsor
- Reata Pharmaceuticals
- Start
- Feb 2020
- Modality
- Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised trial in autosomal dominant polycystic kidney disease (ADPKD) comparing Bardoxolone methyl with Placebo (2 arms). Started Feb 2020; status: completed.
02
Drugs
bardoxolone methyl
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on jRCT2080225066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225066.